IGHE and Increased total eosinophil count: Among these, treatment complications were responsible for discontinuation in one patient on dupilumab, diagnosed with hypereosinophilia; the subject started therapy with blood eosinophilia 630 G/l, without reported atopic conditions and with unknown total serum IgE level.